Articles tagged with: Cancer Vaccine
News»
This article is the fifth in a five-part series about emerging vaccines for multiple myeloma. It tells the story of a patient who participated in a myeloma vaccine clinical trial. The first article in the series provides an introduction to the concept of a myeloma vaccine, the second article provides an introduction to the various types of myeloma vaccines that are currently under development, the third article describes vaccines for which clinical trials have been completed, and the fourth article focuses on ongoing myeloma vaccine research.
Tom Liebert …
News»
This article is the fourth in a five-part series about emerging vaccines for multiple myeloma. It focuses on ongoing myeloma vaccine research. The first article in the series provides an introduction to the of a myeloma vaccine, the second article provides an introduction to the various types of myeloma vaccines that are currently under development, and the third article describes vaccines for which clinical trials have been completed. The fifth article tells the story of a patient who participated in a myeloma vaccine clinical trial.
Vaccine therapy …
News»
This article is the third in a five-part series about emerging vaccines for multiple myeloma. It describes vaccines for which clinical trials have been completed. The first article in the series provides an introduction to the concept of a myeloma vaccine, and the second article provides an introduction to the various types of myeloma vaccines that are currently under development. The fourth article focuses on ongoing vaccine research, and the fifth article tells the story of a patient who participated in a myeloma vaccine clinical trial.
Clinical trials …
News»
This article is the second in a five-part series about emerging vaccines for multiple myeloma. It provides an introduction to the various types of vaccines that are currently under development for myeloma. The first article in the series provided an introduction to the concept of a myeloma vaccine. The third article describes vaccines for which clinical trials have been completed, the fourth article focuses on ongoing vaccine research, and the fifth article tells the story of a patient who participated in a myeloma vaccine clinical trial.
As …
News»
This article is the first in a five-part series about emerging vaccines for multiple myeloma. It provides an introduction to the concept of a myeloma vaccine. The second article provides an introduction to the various types of vaccines that are currently under development for myeloma, the third article describes vaccines for which clinical trials have been completed, the fourth article focuses on ongoing vaccine research, and the fifth article tells the story of a patient who participated in a myeloma vaccine clinical trial.
A Search For The …
News»
The results of a recent Phase 1 trial demonstrate that a multiple myeloma vaccine produced disease stabilization in the majority of enrolled myeloma patients with advanced disease.
Researchers from Beth Isreael Deaconess Medical Center and Dana Farber Cancer Institute designed an anti-myeloma vaccine by combining myeloma tumor cells with dendritic cells, a type of cell that helps activate the immune system. When administered to patients, the vaccine stimulates the immune system to form a response against myeloma proteins. As a result, the immune system recognizes myeloma cells as “foreign” and will destroy …
NewsFlash »
LLS Increases Financial Support For Myeloma Patients - As of Feb 1, the Leukemia & Lymphoma Society (LLS) will provide multiple myeloma patients with up to $10,000 to cover insurance-related expenses such as co-payments and insurance premiums. The new limit is an increase from the previous limit of $5,000 and is retroactive for expenses beginning July 1, 2009. For more information or to apply, please see the LLS Co-Pay Assistance Web site.
Carfilzomib Phase 3 Clinical Trial Design Is Approved – Onyx Pharmaceuticals, Inc. announced that it has reached an agreement with the Food and Drug Administration on the design and analysis of a Phase 3 clinical trial evaluating carfilzomib in relapsed myeloma. The study follows up a Phase 1B trial that examined carfilzomib in combination with Revlimid (lenalidomide) and dexamethasone (Decadron) (see related Beacon news). The Phase 3 trial is expected to begin in early to mid 2010, and the Phase 1b/2 study of this combination regimen is still recruiting participants. For more information, please see the Onyx press release.
Cancer Vaccine Produces Positive Results In Multiple Myeloma Patient – Results from a study evaluating the effects of a high dose cancer vaccine in patients with multiple myeloma, myelodysplastic syndromes, and acute myeloid leukemia showed positive immune responses in several patients. The vaccine helps the immune system kill cancer cells by building up antibodies to a protein called RHAMM, which is associated with cancer progression. In one of the three myeloma patients, the vaccine led to a decrease of the patient’s free light chains, from 10.3 mg/L to 2.26 mg/L. Side effects were limited to mild redness and infection of the skin. For more information, please see the journal Haematologica (pdf).